C. Quivoron

发表

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

P. Opolon, E. Solary, W. Vainchenker, 2011, Cancer cell.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Claude Preudhomme, Robert Barouki, Serge Koscielny, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

J. Bourhis, S. Broutin, A. Paci, 2015 .

JAK2V617F/TET2 mutations: does the order matter?

E. Pronier, O. Bernard, J. Villeval, 2011, Haematologica.

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Hua Yang, K. Yen, O. Bernard, 2014 .

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

S. Gross, Giovanni Cianchetta, Cheng Fang, 2018, ACS medicinal chemistry letters.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model

A. Kernytsky, Yaguang Si, S. Gross, 2016, Journal of Inherited Metabolic Disease.

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

F. Pasquier, F. Rosselli, S. de Botton, 2021, HemaSphere.

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B‐cell lymphoma: Results of LNH‐EP1 study

J. Soria, L. Lacroix, J. Rossignol, 2021, American journal of hematology.

[In cauda venenum or the importance of TET(2)].

W. Vainchenker, O. Bernard, C. Bastard, 2011, Medecine sciences : M/S.

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor

E. Oberlin, Hind Guénou, G. Uzan, 2022, Stem cell research & therapy.

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice

P. Opolon, O. Bernard, V. Penard-Lacronique, 2014, Leukemia.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

S. Broutin, J. Delahousse, A. Paci, 2018, Leukemia.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

B-cell tumor development in Tet2-deficient mice.

O. Bernard, P. Dessen, M. Fontenay, 2018, Blood advances.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.

TET2, a tumor suppressor in hematological disorders.

W. Vainchenker, O. Bernard, C. Bastard, 2012, Biochimica et biophysica acta.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study

F. Pasquier, E. Clappier, S. Broutin, 2020, Leukemia & lymphoma.

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.

S. Broutin, A. Paci, V. Penard-Lacronique, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

T. Molina, F. Jardin, G. Salles, 2020 .

Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study

O. Bernard, V. Ribrag, C. Quivoron, 2023, Cancers.

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

A. Aupérin, V. Ribrag, C. Massard, 2022, Haematologica.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, E. Solary, O. Bernard, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study

A. Hollebecque, C. Massard, C. Quivoron, 2021 .

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

D. Planchard, Y. Loriot, C. Quivoron, 2024, The Journal of Liquid Biopsy.